Back
Cara Therapeutics 10K Form
Buy
51
CARA
Cara Therapeutics
Last Price:
0.35
Seasonality Move:
3.84%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-13 | 10Q | CARA/Cara Therapeutics Quarterly |
| 2023-11-13 | 10Q | CARA/Cara Therapeutics Quarterly |
| 2023-08-07 | 10Q | CARA/Cara Therapeutics Quarterly |
| 2023-05-15 | 10Q | CARA/Cara Therapeutics Quarterly |
| 2022-11-07 | 10Q | CARA/Cara Therapeutics Quarterly |
| 2022-08-08 | 10Q | CARA/Cara Therapeutics Quarterly |
Receive CARA News And Ratings
See the #1 stock for the next 7 days that we like better than CARA
CARA Financial Statistics
Sales & Book Value
| Annual Sales: | $20.97M |
|---|---|
| Cash Flow: | $-12.65M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.21 |
| Price / Book: | 1.61 |
Profitability
| EPS (TTM): | -2.04000 |
|---|---|
| Net Income (TTM): | $-111.08M |
| Gross Margin: | $14.79M |
| Return on Equity: | -189.52% |
| Return on Assets: | -103.2% |
Cara Therapeutics Earnings Forecast
Key Cara Therapeutics Financial Ratios
- The Gross Profit Margin over the past 8 years for CARA is 70.56%.
- The Selling, General & Administrative Expenses for CARA have been equal to 131.86% of Gross Profit Margin.
- The Research & Development expenses have been 517.50% of Revenue.
- The Interest Expense is -0.51% of Operating Income.
- The Net Earning history of CARA is -565.21% of Total Revenues.
- Per Share Earnings over the last 13 years have been positive in 5 years.
Cara Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | CARA |
| CUSIP: | 140755 |
| Website: | caratherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 4.59 |
| Quick Ratio: | 4.2 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
CARA Technical Analysis vs Fundamental Analysis
Buy
51
Cara Therapeutics (CARA)
is a Buy
Is Cara Therapeutics a Buy or a Sell?
-
Cara Therapeutics stock is rated a Buy
The current Cara Therapeutics [CARA] share price is $0.34. The Score for CARA is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.